11 June 2010
NHS Evidence – eyes and vision is pleased to present an Evidence Update on AMD, one of the commonest causes of certifiable visual impairment in the UK – see http://bit.ly/evscbX2HTj
The 2010 Evidence Update focuses on the management of neovascular (wet) AMD and highlights the:
– key evidence base underpinning current interventions (key randomised controlled trials and current guidance);
– new evidence that is likely to inform a change in clinical practice;
– emerging evidence for Lucentis, Avastin and combination treatments from key RCTs that have recently reported at scientific conferences but not yet published in peer reviewed literature;
– current uncertainties in the effectiveness of treatments.
Commentaries have been provided by Robin Hamilton, Consultant Ophthalmic Surgeon, Moorfields Eye Hospital NHS Foundation Trust, Praveen Patel, Locum Consultant Ophthalmologist, Moorfields Eye Hospital NHS Foundation Trust and Darwin Minassian and Angela Reidy, EpiVision.
– Ranibizumab (Lucentis): Rationale for current practice: Current recommended treatment regime.
– Emerging evidence for the frequency of treatment with anti-VEGF agents in neovascular AMD.
– AMD – Future sight loss from AMD. Future Sight Loss UK (2): An epidemiological and economic model for sight loss in the decade 2010-2020.
If you require any further information about the update or NHS Evidence – eyes and vision, please contact Karen Poole on Karen.Poole@moorfields.nhs.uk